Esperion Therapeutics, Inc. Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Pct in Hypercholesterolemic Patients With Type 2 Diabetes
Staying up-to-date has never been simpler. Sign up for the free
GenePool newsletter today!
LAKE BUENA VISTA, Fla.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. Esperion Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announced full results of a Phase 2 clinical trial of ETC-1002 in patients with Type 2 diabetes and hypercholesterolemia. The trial met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by up to 43 percent and was associated with improvements in control of other cardiometabolic risk factors. In addition, ETC-1002 was well tolerated.
Help employers find you! Check out all the jobs and post your resume.
LAKE BUENA VISTA, Fla.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. Esperion Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announced full results of a Phase 2 clinical trial of ETC-1002 in patients with Type 2 diabetes and hypercholesterolemia. The trial met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by up to 43 percent and was associated with improvements in control of other cardiometabolic risk factors. In addition, ETC-1002 was well tolerated.
Help employers find you! Check out all the jobs and post your resume.